← Back to Search

Checkpoint Inhibitor

Pembrolizumab for Breast Cancer

Q: What medical conditions is Ruxolitinib Phosphate prescribed to alleviate?

<p>Patients with unresectable <a href="https://www.withpower.com/clinical-trials/melanoma">melanoma</a>, high microsatellite instability and a heightened risk of recurrence may benefit from Ruxolitinib Phosphate treatment.</p>

Phase 1

Waitlist Available

Led By Donald W Northfelt

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 years

Awards & highlights

Study Summary

This trial is testing the side effects and best dose of a drug when given with another drug to treat stage IV triple negative breast cancer.

Eligible Conditions

Triple Negative Breast Cancer
Bone Metastasis
Breast Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of adverse events

Maximum tolerated dose

Secondary outcome measures

Best response

Other outcome measures

Assessment of PDJ amplification, PD-L1, PD-L2, JAK2 expression and pSTAT3

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (pembrolizumab, ruxolitinib phosphate)Experimental Treatment3 Interventions

Patients receive pembrolizumab IV over 30 minutes on day 1 and ruxolitinib phosphate PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Pembrolizumab

2017

Completed Phase 2

~2010

Ruxolitinib Phosphate

2011

Completed Phase 2

~390

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,654 Previous Clinical Trials

40,933,141 Total Patients Enrolled

940 Trials studying Breast Cancer

1,543,360 Patients Enrolled for Breast Cancer

Mayo ClinicLead Sponsor

3,205 Previous Clinical Trials

3,766,772 Total Patients Enrolled

83 Trials studying Breast Cancer

13,912 Patients Enrolled for Breast Cancer

Donald W NorthfeltPrincipal InvestigatorMayo Clinic

Media Library

Pembrolizumab (Checkpoint Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03012230 — Phase 1

Breast Cancer Research Study Groups: Treatment (pembrolizumab, ruxolitinib phosphate)

Breast Cancer Clinical Trial 2023: Pembrolizumab Highlights & Side Effects. Trial Name: NCT03012230 — Phase 1

Pembrolizumab (Checkpoint Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03012230 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA sanctioned Ruxolitinib Phosphate for public consumption?

"With limited clinical evidence of efficacy and safety, our team at Power assigned Ruxolitinib Phosphate a score of 1 on the risk assessment scale."

Answered by AI

How many participants has this medical trial recruited thus far?

"Affirmative. According to the info available on clinicaltrials.gov, this trial is actively enrolling participants with its first posting being on December 6th 2017 and most recent update occurring on October 21st 2022. 18 patients from a single site are expected to join the study."

Answered by AI

What precedent has been set for Ruxolitinib Phosphate in clinical research?

"A comprehensive search of clinical trials.gov reveals 1058 registered studies researching Ruxolitinib Phosphate, with 134 in their late stages of development. The majority are based around Houston, Texas; however there are 38968 locations across the globe currently running these tests."

Answered by AI

Is this research study still welcoming new participants?

"According to the information made available on clinicaltrials.gov, this study is actively searching for participants. It was initially published in December of 2017 and underwent its most recent revision in October of 2022."

Answered by AI

What medical conditions is Ruxolitinib Phosphate prescribed to alleviate?

"Patients with unresectable melanoma, high microsatellite instability and a heightened risk of recurrence may benefit from Ruxolitinib Phosphate treatment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer

2017. "Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03012230.